What are the possible side effects and hazards of ibrutinib/Eco?

Ibrutinib/Ibrutinib (Ibrutinib) is an oral Bruton's tyrosine kinase (BTK) inhibitor, widely used in the treatment of chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), small lymphocytic lymphoma (SLL) and Waldenstrom's macroglobulinemia and other B cell-related diseases. BTK plays a key role in the B cell receptor signaling pathway. By inhibiting its activity, ibrutinib can block abnormal B cell proliferation and survival, thereby achieving disease control. However, as a targeted drug, the use of ibrutinib may also be associated with certain adverse reactions and potential hazards.

In clinical practice, the most common side effects of ibrutinib include bleeding tendency, abnormal platelet function, mild to moderate arrhythmia, gastrointestinal discomfort, rash, fatigue, joint and muscle pain, diarrhea, nausea, and decreased appetite. Most of these side effects can be controlled through dose adjustment or symptomatic treatment, but in a small number of patients, serious or life-threatening adverse events may occur. In particular, bleeding events, including nosebleeds, gum bleeding, and skin ecchymosis, need to be taken seriously and used with caution when anticoagulants or antiplatelet drugs are combined.

In addition, long-term use of ibrutinib may have effects on the cardiovascular system, such as an increased risk of atrial fibrillation or arrhythmia, especially in patients with previous cardiovascular disease. Therefore, cardiac evaluation needs to be performed before taking the drug, and electrocardiogram and heart rate should be monitored regularly during treatment. Adverse reactions related to the immune system also require attention. Some patients may have an increased risk of infection, such as respiratory or urinary tract infections, which is related to inhibition of B cell function.

In terms of laboratory indicators, ibrutinib may cause changes in white blood cells, platelets, and hemoglobin levels, and liver function indicators such as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) may increase. Therefore, patients need to regularly monitor hematology and liver and kidney function indicators during the medication period in order to detect abnormalities in time and adjust the treatment plan.

Reference materials:https://www.imbruvica.com/